Exact claim · Version 1 · Reviewed 2026-07-23
“Tesamorelin reduces visceral fat in adults with HIV-associated lipodystrophy.”
A verdict on this wording and scope, not a universal grade for Tesamorelin.
01 · Verdict
Supported with scope
Phase 3 trials and the product label support this outcome in the labeled population.
- Evidence basis
- Randomized human outcomes
- Scope
- Adults with HIV and excess abdominal fat meeting the trial and label criteria.
- Category
- Body composition
02 · Primary record
Check the attached evidence
01Tesamorelin in HIV-associated abdominal fat accumulationPubMed · Journal of Acquired Immune Deficiency Syndromes · Randomized trial · 2010
Supports the scoped claim02EGRIFTA SV (tesamorelin) prescribing informationU.S. Food and Drug Administration · Drug label · 2024
Supports the scoped claim03EGRIFTA WR (tesamorelin) prescribing informationU.S. Food and Drug Administration · Drug label · 2025
Supports the scoped claim
Supports the scoped claim02EGRIFTA SV (tesamorelin) prescribing informationU.S. Food and Drug Administration · Drug label · 2024
Supports the scoped claim03EGRIFTA WR (tesamorelin) prescribing informationU.S. Food and Drug Administration · Drug label · 2025
Supports the scoped claim
- Editorial review
- Internal editorial review recorded
- Responsible editor
- Anthony Treviso · Founder and responsible editor
- Clinical-review boundary
- Not independently medically reviewed.